{
    "clinical_study": {
        "@rank": "94310", 
        "arm_group": {
            "arm_group_label": "infusions of EBV specific cytotoxic T lymphocytes", 
            "arm_group_type": "Experimental", 
            "description": "Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and those achieving partial remission are followed weekly for signs of disease progression"
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Donor lymphocytes that have been exposed to Epstein-Barr virus may be able to\n      help the body kill cancers associated with this virus.\n\n      PURPOSE: Phase I trial to study the effectiveness of Epstein-Barr virus-specific T cells\n      derived from matched donors in organ transplant patients with lymphoproliferative diseases\n      associated with Epstein-Barr virus."
        }, 
        "brief_title": "Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants", 
        "completion_date": {
            "#text": "February 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Leukemia", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Lymphoma", 
                "Lymphoproliferative Disorders", 
                "Lymphoma, Large-Cell, Immunoblastic"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Examine the toxic effects of allogeneic Epstein-Barr virus (EBV) specific\n      cytotoxic T lymphocytes (CTL) for the treatment of EBV lymphoproliferative diseases (LPD) in\n      organ transplant recipients. II. Determine the level of in vivo expansion of allogeneic CTL\n      and the period of time during which these CTL's can be detected in the blood of recipients\n      of the T cell infusions.\n\n      OUTLINE: Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T\n      lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T\n      lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and\n      those achieving partial remission are followed weekly for signs of disease progression.\n\n      PROJECTED ACCRUAL: 10 patients will be accrued in this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Radiographic evidence of lymphadenopathy or lymphomatous lesions\n        combined with clinical signs of Epstein-Barr virus lymphoproliferative disease (EBV LPD),\n        such as fevers and lymphadenopathy, following an organ transplant Persistent, progressive,\n        or unresponsive disease despite decreased immunosuppression, chemotherapy, or radiation\n        therapy EBV LPD must be of host origin\n\n        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life\n        expectancy: At least 4 weeks Hematopoietic: Not specified Hepatic: Patients serologically\n        hepatitis B and C positive may receive cytotoxic T lymphocytes (CTL) from donors who are\n        serologically positive for the same virus No hepatic dysfunction SGOT/SGPT less than 2.5\n        times upper limit of normal (unless liver metastases present) Bilirubin less than 2.0\n        mg/dL Renal: No renal dysfunction Creatinine clearance at least 50 mL/min Cardiovascular:\n        No cardiac dysfunction Neurologic: No neurologic dysfunction Pulmonary: No pulmonary\n        dysfunction Other: (patient) Must have an HLA identical or HLA haploidentical donor No\n        patients developing EBV LPD who have a donor origin lymphoma Patients serologically\n        positive for cytomegalovirus positive may receive CTL from donors who are serologically\n        positive for the same virus (donor) Not HIV-1 positive Medically fit to undergo\n        leukapheresis Donor CTL must be capable of lysing patient B lymphoblastoid cell line\n        (BLCL) in vitro\n\n        PRIOR CONCURRENT THERAPY: Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002956", 
            "org_study_id": "CDR0000065433", 
            "secondary_id": [
                "UAB-9739", 
                "IUMC-9611-37", 
                "NCI-V97-1176"
            ]
        }, 
        "intervention": {
            "arm_group_label": "infusions of EBV specific cytotoxic T lymphocytes", 
            "intervention_name": "allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "recurrent adult Hodgkin lymphoma", 
            "recurrent childhood lymphoblastic lymphoma", 
            "childhood diffuse large cell lymphoma", 
            "childhood immunoblastic large cell lymphoma", 
            "recurrent/refractory childhood Hodgkin lymphoma", 
            "T-cell large granular lymphocyte leukemia", 
            "recurrent grade 1 follicular lymphoma", 
            "recurrent grade 2 follicular lymphoma", 
            "recurrent grade 3 follicular lymphoma", 
            "recurrent adult diffuse small cleaved cell lymphoma", 
            "recurrent adult diffuse mixed cell lymphoma", 
            "recurrent adult diffuse large cell lymphoma", 
            "recurrent adult immunoblastic large cell lymphoma", 
            "recurrent adult lymphoblastic lymphoma", 
            "recurrent adult Burkitt lymphoma", 
            "recurrent childhood small noncleaved cell lymphoma", 
            "recurrent childhood large cell lymphoma", 
            "recurrent mantle cell lymphoma", 
            "recurrent marginal zone lymphoma", 
            "recurrent small lymphocytic lymphoma", 
            "extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue", 
            "nodal marginal zone B-cell lymphoma", 
            "splenic marginal zone lymphoma"
        ], 
        "lastchanged_date": "August 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35294"
                }, 
                "name": "University of Alabama Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Pilot Trial to Evaluate the Toxicity of Allogeneic Epstein-Barr Virus Specific T-Lymphocytes for the Treatment of EBV-Associated Lymphoproliferative Diseases in Organ Transplant Recipients", 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "Kenneth G. Lucas, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of adverse events associated with administration of allogeneic Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTL) for the treatment of EBV lymphoproliferative diseases (LPD) in organ transplant recipients", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to   x weeks post infusion"
            }, 
            {
                "measure": "Mean length of time of allogeneic CTL  during which these CTL's can be detected in the blood of recipients of the T cell infusions.", 
                "safety_issue": "No", 
                "time_frame": "baseline to x weeks past infusion"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 1996", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }, 
    "geocoordinates": {
        "University of Alabama Comprehensive Cancer Center": "33.521 -86.802"
    }
}